Q2 2023 · 13F-HR
MPM BioImpact LLCholdings as filed
Filed 2023-08-14 · accession 0000950123-23-007806
$496.6M
Reported value
34
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 230031106 | CGEM | Cullinan Oncology, Inc. | $82.3M | 16.6% | 7,648,268 | Common | SOLE |
| 46583P102 | — | Iveric Bio Inc | $47.8M | 9.62% | 1,214,662 | Common | SOLE |
| 16961L106 | — | Chinook Therapeutics, Inc. | $38.6M | 7.76% | 1,003,406 | Common | SOLE |
| 374163103 | GERN | Geron Corporation | $29.5M | 5.94% | 9,191,290 | Common | SOLE |
| 75615P103 | — | Reata Pharmaceuticals, Inc. | $23.9M | 4.81% | 234,478 | Common | SOLE |
| 46565G104 | 5E7 | iTeos Therapeutics, Inc. | $23.1M | 4.65% | 1,745,943 | Common | SOLE |
| 45826J105 | NTLA | Intellia Therapeutics, Inc. | $22.2M | 4.47% | 544,639 | Common | SOLE |
| 462260100 | IOVA | Iovance Biotherapeutics Inc | $20.8M | 4.18% | 2,950,118 | Common | SOLE |
| 760273102 | RPTX | Repare Therapeutics, Inc. | $17.3M | 3.49% | 1,639,849 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics Inc. | $17.0M | 3.43% | 1,354,368 | Common | SOLE |
| 92539P101 | — | Verve Therapeutics, Inc | $16.1M | 3.24% | 857,940 | Common | SOLE |
| 61559X104 | MLTX | Moonlake Immunotherapeutics | $15.1M | 3.03% | 295,111 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO Inc. | $13.1M | 2.64% | 656,718 | Common | SOLE |
| 48576A100 | — | Karuna Therapeutics Inc | $11.6M | 2.33% | 53,399 | Common | SOLE |
| 457669307 | INSM | Insmed Incorporated | $11.2M | 2.25% | 529,743 | Common | SOLE |
| 98422E103 | XERS | Xeris Biopharma Holdings Inc | $10.4M | 2.10% | 3,974,999 | Common | SOLE |
| 558868105 | MDGL | Madrigal Pharmaceuticals inc | $8.8M | 1.77% | 38,011 | Common | SOLE |
| 22663K107 | CRNX | Crinetics Pharmaceuticals Inc. | $8.6M | 1.74% | 479,053 | Common | SOLE |
| 89422G107 | TVTX | Travere Therapeutics Inc. | $8.5M | 1.71% | 552,846 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines, Inc. | $7.3M | 1.47% | 273,408 | Common | SOLE |
| 95075A107 | HOWL | Werewolf Therapeutics, Inc. | $7.3M | 1.47% | 2,388,011 | Common | SOLE |
| 483497103 | KALV | Kalvista Pharmaceuticals Inc | $6.9M | 1.38% | 761,538 | Common | SOLE |
| 05464T104 | AXSM | Axsome Therapeutics, Inc. | $6.7M | 1.35% | 93,586 | Common | SOLE |
| 03152W109 | AM6 | Amicus Therapeutics Inc. | $6.5M | 1.31% | 516,139 | Common | SOLE |
| 05337M104 | — | Avadel Pharmaceuticals PLC | $6.3M | 1.28% | 384,990 | Common | SOLE |
| 92790C104 | VRDN | Viridian Therapeutics Inc | $6.1M | 1.22% | 255,323 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics Inc | $5.5M | 1.11% | 712,798 | Common | SOLE |
| 00653A107 | ADAPY | Adaptimmune Therapeutics plc | $4.7M | 0.95% | 5,095,912 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals, Inc. | $4.2M | 0.84% | 462,500 | Common | SOLE |
| 71722W107 | PHAT | Phathom Pharmaceuticals inc | $4.0M | 0.81% | 282,332 | Common | SOLE |
| 41358P106 | — | Harpoon Therapeutics, Inc. | $2.3M | 0.46% | 3,196,707 | Common | SOLE |
| 45790W108 | — | Inozyme Pharma Inc. | $1.8M | 0.37% | 326,921 | Common | SOLE |
| 92332V107 | VTYXUSD | Ventyx Biosciences Inc | $1.0M | 0.21% | 31,747 | Common | SOLE |
| 68236R103 | — | Oncorus, Inc. | $96,270 | 0.02% | 2,377,031 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.